Pharming Group NV News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

19.05.21	Pharming Reports on Annual General Meeting of Shareholders (PR Newswire)
17.05.21	Pharming celebrates the 10th annual "hae day :-)" (PR Newswire)
13.05.21	Pharming Group reports financial results for the first quarter of 2021 (PR Newswire)
11.05.21	Ausblick: Pharming Group NV präsentiert Bilanzzahlen zum jüngsten Jahresviertel (finanzen.net)
28.04.21	Erste Schätzungen: Pharming Group NV präsentiert Bilanzzahlen zum jüngsten Jahresviertel (finanzen.net)
22.04.21	Pharming announces enrolment of first patient in multicentre Phase IIb clinical trial of RUCONEST® for the prevention of acute kidney injury after myocardial infarction (PR Newswire)
07.04.21	Pharming Group announces the filing of its 2020 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (PR Newswire)
06.04.21	Pharming Group announces the publication of its 2020 Annual Report and convenes its 2021 AGM (PR Newswire)
23.03.21	Pharming Group announces the intention to nominate three Non-Executive Directors to the Board of Directors (PR Newswire)
16.03.21	Pharming Group to present at 31st Annual Oppenheimer Healthcare Conference (PR Newswire)
11.03.21	Pharming Group to Present at BioCapital Europe 2021 (PR Newswire)
04.03.21	Pharming Group reports financial results for full year 2020 (PR Newswire)
02.03.21	Ausblick: Pharming Group NV zieht Bilanz zum jüngsten Jahresviertel (finanzen.net)
02.03.21	Pharming Group, in collaboration with Invitae Corporation, launches genetic testing program 'navigateAPDS' in US and Canada (PR Newswire)
16.02.21	Erste Schätzungen: Pharming Group NV legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net)
23.12.20	Pharming Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq Listed ADSs (PR Newswire)
23.12.20	Pharming Group announces ADSs admitted to trade on Nasdaq under the symbol "PHAR" (PR Newswire)
11.12.20	Pharming Reports on Extraordinary General Meeting of Shareholders (PR Newswire)
10.12.20	Pharming announces enrolment of first patient in US clinical trial for the treatment of COVID-19 with RUCONEST® (PR Newswire)
26.11.20	Pharming Group Publicly Files Registration Statement with the U.S. SEC to Facilitate Listing of ADSs Representing Ordinary Shares on Nasdaq Global Market (PR Newswire)
23.11.20	Juergen Ernst to retire from Pharming's Board of Supervisory Directors after more than 11 years of distinguished service (PR Newswire)
19.11.20	Pharming announces commitment to build a new downstream manufacturing facility for RUCONEST® (PR Newswire)
09.11.20	Pharming appoints Jeroen Wakkerman as Chief Financial Officer (PR Newswire)
29.10.20	Pharming convenes Extraordinary General Meeting of shareholders (PR Newswire)
29.10.20	Pharming Group reports financial results for the first nine months of 2020 (PR Newswire)
28.10.20	Ausblick: Pharming Group NV zieht Bilanz zum abgelaufenen Quartal (finanzen.net)
21.10.20	Pharming receives Orphan Drug Designation from the European Commission for leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) (PR Newswire)
14.10.20	Erste Schätzungen: Pharming Group NV veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net)
17.08.20	Pharming announces the publication of data from a compassionate use programme of RUCONEST® in COVID-19 patients in a peer-reviewed journal (PR Newswire)
10.08.20	Pharming announces enrolment of first patient in multinational clinical trial for the treatment of COVID-19 with RUCONEST® (PR Newswire)
30.07.20	Pharming Group reports financial results for the first half of 2020 (PR Newswire)
29.07.20	Ausblick: Pharming Group NV gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net)
15.07.20	Erste Schätzungen: Pharming Group NV stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net)
20.05.20	Pharming Reports on Annual General Meeting of Shareholders (PR Newswire)
20.05.20	Pharming Group Announces the Nomination of Barbara Yanni and Mark Pykett to the Board of Supervisory Directors (PR Newswire)
14.05.20	Pharming Group Reports Financial Results for the First Quarter of 2020 (PR Newswire)
21.04.20	Pharming Reports Encouraging Results From Use of RUCONEST® in COVID-19 Patients (PR Newswire)
08.04.20	Pharming Group Convenes Annual General Meeting of Shareholders (PR Newswire)
23.03.20	Pharming Enters the Euronext Amsterdam Midkap-index (AMX) (PR Newswire)
11.03.20	Pharming CFO to Step Down (PR Newswire)
09.03.20	Pharming Receives FDA Approval of New Facility for Expansion of RUCONEST® Production (PR Newswire)
05.03.20	Pharming Group Reports Strong Preliminary (Unaudited) Financial Results for 2019 (PR Newswire)
04.03.20	Ausblick: Pharming Group NV öffnet die Bücher zum abgelaufenen Quartal (finanzen.net)
21.01.20	Pharming Receives EMA Approval of New Facility for Expansion of RUCONEST® Production (PR Newswire)
14.01.20	Pharming Announces the Placement of €125 Million Senior Unsecured Convertible Bonds Due 2025 (PR Newswire)
30.12.19	Pharming Reacquires RUCONEST®-licensed Territories from Sobi (PR Newswire)
24.10.19	Pharming Group Reports Strong Interim Financial Results for the First Nine Months of 2019 (PR Newswire)
23.10.19	Ausblick: Pharming Group NV legt Zahlen zum jüngsten Quartal vor (finanzen.net)
13.08.19	Pharming Acquires Exclusive License to CDZ173, a Late Stage Drug for the Treatment of APDS (PR Newswire)
24.07.19	Ausblick: Pharming Group NV zieht Bilanz zum abgelaufenen Quartal (finanzen.net)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Pharming Group NV

Aktien Top/Flop

Meistgelesene Nachrichten